SEC EDGAR · Company announcement
MRNA: Financial results
Filed 8-K for an event or period dated 2026-07-31. Financial results.
Follow MRNA- Became public
- Jul 31, 2026, 7:03 AM EDT
- Event / period date
- Jul 31, 2026
- Collected
- Nov 9, 2026, 1:46 PM EST
Why this is connected
This filing identifies Moderna, Inc. as the issuer of the security. The company's SEC identifier connects it to MRNA.
Press release issued by Moderna, Inc. dated ↗Source evidence
Read the source excerpt or record
Item 2.02 Results of Operations and Financial Condition. On July 31, 2026, Moderna, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press release issued by Moderna, Inc. dated July 3 1, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MODERNA, INC. Date: July 31, 2026 By: /s/ James M. Mock James M. Mock Chief Financial Officer
Price change after we could observe it
-7.77% MRNA
Adjusted closing prices from Nov 10, 2026 to Nov 12, 2026. SPY changed 0.96% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.
Congressional trading in MRNA
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 10, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
$1K–$15K · Traded Oct 20, 2026 · disclosed Nov 10, 2026
- Nov 5, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Oct 13, 2026 · disclosed Nov 5, 2026 · Spouse
- Oct 7, 2026$1K–$15K
Rep. Maria Elvira Salazar (R-FL-27)
$1K–$15K · Traded Sep 24, 2026 · disclosed Oct 7, 2026
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 11, 2026 · disclosed Oct 7, 2026 · Dependent
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Sep 9, 2026$1K–$15K
Rep. Maria Elvira Salazar (R-FL-27)
$1K–$15K · Traded Aug 19, 2026 · disclosed Sep 9, 2026
- Sep 9, 2026$1K–$15K
Rep. Maria Elvira Salazar (R-FL-27)
$1K–$15K · Traded Aug 19, 2026 · disclosed Sep 9, 2026
- Feb 6, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Jan 29, 2026 · disclosed Feb 6, 2026 · Spouse
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.